Q&A on the Johnson & Johnson COVID-19 vaccine with Mona Chitre, PharmD, Chief Pharmacy Officer and Vice President of Clinical Strategy and Innovation at Excellus BlueCross BlueShield

Posted on March 9, 2021

Dr. Chitre leads Excellus BlueCross BlueShield’s pharmacy strategy and is responsible for driving affordability, innovation and operational excellence. She completed her undergraduate and graduate training at Rutgers University and her post-doctoral primary care residency at the Buffalo VA Medical Center in Buffalo, New York.

Q: Dr. Chitre, the Johnson & Johnson (J&J) vaccine is the third COVID-19 vaccine being distributed in the U.S. Is it safe? Why do we need a third vaccine option?
A: All vaccines have the same goal – to protect us. The J&J vaccine was tested thousands of times to ensure safety and is authorized for use in the U.S. It’s important that everyone who wants the COVID-19 vaccine can receive it. In addition to the Moderna and Pfizer-BioNTech vaccines, the J&J vaccine is another way to help increase protection against the virus that causes COVID-19. Since all three vaccines are safe, the best vaccine is the one you have access to.

Q: How does the J&J vaccine differ from Moderna’s and Pfizer-BioNTech’s?
A: The J&J vaccine is a single dose which offers maximum protection quicker than Moderna’s and Pfizer-BioNTech’s vaccines. The J&J vaccine has proven to be 66% effective at preventing moderate to severe cases of COVID-19. With all three vaccine options, no fragment of the live virus is in the vaccine so the vaccine itself cannot make you sick with COVID-19.

Q: Should we be concerned with a less effective rate?
A: No, there is no need to be concerned. The only way to accurately compare the effectiveness of these vaccines is by direct comparison in head-to-head clinical trials, which did not happen across the three vaccine options. Testing took place in different regions, at different points in time, and with varying COVID-19 occurrences. It is best not to compare the effective rates between the vaccines.

The data proves that the J&J vaccine is 85% effective against severe COVID-19 cases, and 100% effective at preventing death from COVID-19. Based on the data, the J&J vaccine is a very safe and effective option.

Q: There is mention of a booster vaccine to help protect against the COVID-19 variants. What information is known or suggested about this?

A: Scientists are currently looking into if a booster dose is needed to address variants. It is emerging science at this time, but it is still recommended that you get your vaccine as soon as it is available for you.

Q: We know that vaccines were given to high-risk groups first. The data suggests that the number of deaths in nursing homes is going down by more than 60%. Do you feel this is because of the vaccine?
A: Absolutely. Nursing home residents were among the first people to receive the vaccine. The data shows how powerful the vaccines are against the virus, which is encouraging to hear. Reports like these make me so hopeful as the vaccines continue to rollout. I’m excited for my children to be reunited with their grandparents. I’m optimistic about the future.

Other Network News

Emergent Logo
August 6, 2026

Upcoming Emergent Leader Cohort Beginning October 8th in Syracuse, NY

Join Emergent's upcoming Emergent Leader cohort beginning on October 8th in Syracuse, NY!

Ride_The_Route_2026
August 4, 2026

Ride the Route: Free Interactive Bus Training Sessions Coming This September

Oswego County's Office of Mobility Management is offering two free "Ride the Route" interactive classes designed to help residents feel confident using public transportation. Learn trip planning, bus safety, and take a guided ride with…

A_Soure_For_Love
August 4, 2026

A Force of Love: Celebrating National Nonprofit Day

Join us for A Force of Love, a community celebration honoring National Nonprofit Day and the incredible organizations that make Oswego County stronger every day.

NBT Bancorp Inc. Announces Second Quarter 2026 Results and Approves an 8.1% Cash Dividend Increase
August 3, 2026

NBT Bancorp Inc. Announces Second Quarter 2026 Results and Approves an 8.1% Cash Dividend Increase

NBT Bancorp Inc. (“NBT” or the “Company”) (NASDAQ: NBTB) reported net income and diluted earnings per share for the three and six months ended June 30, 2026.

Nave's Neighbors
August 3, 2026

Nave Law Firm Recognizes Nascentia Health as August's Nave's Neighbor

Nave Law Firm highlights Nascentia Health's mission to bring skilled nursing, rehabilitation, and long-term care directly into the homes of thousands of Central New York residents each year.

Ambassadors Graphic 2026
August 3, 2026

Ambassadors-CEO Insights August 2026

CenterState CEO Ambassadors welcome and recognize businesses celebrating grand openings, company anniversaries and other important milestones.

New to the Network
July 30, 2026

Welcome to the CenterState CEO Network-August 2026

Welcome new members to the CenterState CEO Network.

Network News
July 30, 2026

Network News - CEO Insights August 2026

Below is a snapshot of the latest news and top headlines from Members and Clients.

American Red Cross
July 29, 2026

The American Red Cross has Declared a National Blood Crisis

The American Red Cross has Declared a National Blood Crisis